ATOS|EPS -$4.04|Net Loss $34.7MCompany Overview
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on novel therapies for oncology and rare diseases. The company’s lead product candidate currently in clinical development is (Z)-endoxifen.
Key Financial Figures
For the year ended December 31, 2025, Atossa reported a net loss per share (EPS) of $(4.04). Revenue is not reported in the provided financial statements. Total operating expenses for the year reached $37.1 million.
Additional Financial Insights
During 2025, research and development expenses totaled $21.18 million. General and administrative costs amounted to $15.95 million. At the close of the year, the company held $41.29 million in cash and cash equivalents.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.